Researchers at The St. Michael’s Hospital and University of Toronto conducted a meta-analysis of 142 previous clinical trials to compare the safety and effectiveness of four different treatments – donepezil, rivastigmine, galantamine or memantine (and their combinations) in treating moderate to severe Alzheimer’s dementia. The number of participants in each clinical trial ranged from 13 to 2,045.
According to the study, Donepezil+memantine was overall the most effective medication for Alzheimer’s dementia. They also found that Donepezil was the only one that reached the “minimal clinically important difference (MCID)” threshold on the Alzheimer’s Disease Assessment Cognition (ADAS-Cog) scale, and so “is likely a first choice for patients and clinicians considering these agents”.
Link to original study: http://onlinelibrary.wiley.com/doi/10.1111/jgs.15069/epdf